ELV

#185
Elevance Health, Inc. Common Stock
405.7 1 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
405.16
407.63
Jahresspanne
274.84
434.38
Tagesänderung
+0.65%
Monatliche Änderung
+6.00%
6 month change
+42.71%
Jahresänderung
+31.54%
Vorheriger Schlusskurs
403.0 8
Open
406.9 1
Tief
405.1 6
Hoch
407.6 3
Volumen
795
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Elevance Health, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Elevance Health, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Elevance Health, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Elevance Health, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Elevance Health, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Elevance Health, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Elevance Health, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Elevance Health, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Elevance Health, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Elevance Health, Inc. current report, Q1 FY2026
8-K

Elevance Health, Inc. current report, Q1 FY2007

Full document

Business Context and Reporting Period

This Form 8-K filing by WellPoint, Inc. (now Elevance Health, Inc.) reports a significant executive leadership transition. The report date is February 26, 2007, covering events announced on that date with an effective date of June 1, 2007.

Key Financial Metrics

This filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and succession planning.

Material Changes

The primary material change is the appointment of Angela F. Braly as President and Chief Executive Officer, succeeding Larry C. Glasscock, who will retire from the CEO role but remain as non-executive Chairman of the Board.

Guidance, Outlook, and Management Commentary

Management has outlined a specific succession plan approved by the Board of Directors. Key compensation terms for the new CEO and retiring Chairman include:

  • Angela F. Braly (New CEO):
    • Base annual salary: $1,100,000.
    • Target incentive bonus: Not less than 120% of base salary.
    • Severance (No Change in Control): 2x base salary and target bonus if terminated without Cause or for Good Reason.
    • Severance (Change in Control): 3x base salary and target bonus if terminated without Cause or for Good Reason.
    • Equity Grants: Includes stock options for 413,333 shares total and 51,667 Restricted Stock Units (RSUs) across annual awards and special promotional awards, vesting over three years.
  • Larry C. Glasscock (Retiring CEO/Non-Executive Chairman):
    • 2007 Retainer: $437,500 (ineligible for 2007 director equity grants).
    • 2008 Retainer: $500,000.
    • Subsequent Years: $250,000 per year.

The filing notes that Ms. Braly will be subject to restrictive covenants regarding confidentiality, non-competition, and non-solicitation.

Investor Verification Checklist

  • Verify the effective date of the leadership transition (June 1, 2007).
  • Confirm the total equity grant value based on the share counts (413,333 options and 51,667 RSUs) and current stock price.
  • Review the specific definitions of "Cause" and "Good Reason" in the attached Employment Agreement (Exhibit 10.1) to understand severance triggers.
  • Assess the impact of the $437,500 retainer for Mr. Glasscock on 2007 corporate expenses.

Nachrichten